ArticleInflammation2026
Opposing Dynamics of CD4 + Regulatory and CD8 + Foxp3+ T Cells Characterize Immune Imbalance in Rheumatoid Arthritis.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease marked by persistent inflammation and joint damage from impaired immune tolerance. While CD4 + regulatory T cells (Tregs) are key to immune balance, their ability to restore tolerance in RA remains insufficient. Recently, CD8 + Foxp3+T have emerged as distinct regulators of immune tolerance, and investigating their role may provide new insights into the pathogenesis of RA. We enrolled 51 RA patients and 27 healthy controls. RA patients were grouped by disease activity: low-to-moderate (L-M RA) or high (H RA). We analyzed clinical data and lymphocyte subsets, including CD4 + Tregs and CD8 + Foxp3+T, to identify key immunological differences between RA and HC. Internal validation was performed using bootstrapping, and P-values were adjusted for false discovery rate (FDR) to ensure robustness. (1) CD4 + Tregs decreased in RA, especially in H RA, while CD8 + Foxp3+T increased, most in L-M RA. (2) CD4 + Tregs correlated negatively with IL-2, IL-4, and IL-10, whereas CD8 + Foxp3+T correlated negatively with ESR, DAS28, and RF-IgA/IgG. (3) The CD4 + Treg/CD8 + Foxp3+T ratio distinguished RA from controls. The combined model (including TNF-α and CD4 + Treg%) demonstrated strong discrimination with an AUC of 0.928 (optimism-corrected AUC: 0.912). CD8 + Foxp3+ T were increased in patients with RA and exhibited a trend opposite to that of CD4 + Treg. These two cell populations were associated with disease activity from distinct immunological perspectives. Furthermore, the CD4 + Treg/CD8 + Foxp3+T ratio and the combination of CD4 + Treg% with TNF-α showed potential value in distinguishing patients with RA from healthy controls. These findings provide additional insight into the immunological characteristics of RA and support further investigation into the biological significance of CD8 + Foxp3+ T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.